KRAS and non-small cell lung carcinoma: In this study, we retrospectively analyzed the real-world clinical data of advanced KRAS mutant NSCLC patients who received immunotherapy or chemotherapy regimen as first-line treatment, and explored the efficacy and prognosis of patients in different subgroups after diverse treatment regimen, so as to provide some clues for selecting appropriate treatment regimen as first-line therapy for advanced KRAS mutant NSCLC patients in real world.